Creative Biomedical Research Institute
- Assets
- $0.0
- Revenue
- $31.5k
- Investments
- $0.0
- Employees
- 0
- Location
- Philadelphia, PA
- Founding
- 10/2001
- Data as of
- 12/2021
- EIN
- 23-3073872
Organization Overview
Creative Biomedical Research Institute is located in Philadelphia, PA. The organization was established in 2001. According to its NTEE Classification (H30) the organization is classified as: Cancer Research, under the broad grouping of Medical Research and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Creative Biomedical Research Institute is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2021, Creative Biomedical Research Institute generated $31.5k in total revenue. This represents a relatively dramatic decline in revenue. Over the past 6 years, the organization has seen revenues fall by an average of (29.2%) each year. All expenses for the organization totaled $57.3k during the year ending 12/2021. As we would expect to see with falling revenues, expenses have declined by (20.8%) per year over the past 6 years. You can explore the organizations financials more deeply in the financial statements section below.
Form
990PF
Mission & Program ActivityExcerpts From the 990PF Filing
TAX YEAR
2021
Describe the Organization's Program Activity:
Part 3 - Line 4a
LAB RESEARCH - THERE ARE TWO KINDS OF LIVING ORGANISMS; EUKARYOTES INCLUDING HUMANS AND PROKARYOTES INCLUDING PATHOGENIC BACTERIA. IN OUR RESEARCH, THE CBRI IS TRYING TO
FIND NEW ANTIBIOTICS WITH TARGET THE RIBOSOME RECYCLING STEP . IN PROKARYOTES, WE SENT OUT A MANUSCRIPT SUMMARIZING THE MILESTONES OF THE PAST 7 YEARS OF RESEARCH. WE CHARACTERIZED
THE SUBSTRATE, THE TIME COURSE, AND THE KINETIC CONSTANT OF THE REACTION. WE STARTED A NEW KINETIC APPROACH USING A STOP -FLOW MACHINE. WE STARTED TO STUDY THE MECHANISM OF LETHAL
EFFECT OF INNOVATION OF RRF AT THE LAG PHASE. IN THE EUKARYOTIC RECYCLING SYSTEM, WE FOUND A NEW REACTION OF EF-3 , "STIMULATION OF PEPTIDYL HYDROLASE ACTIVITY."
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Akira Kaji Founder, Preseident & CEO | 0 | $0 | |
Michael Kiel Board Member | 0 | $0 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Contributions, Gifts, Grants & Similar | $31,473 |
| Interest on Savings | $1 |
| Dividends & Interest | $0 |
| Net Rental Income | $0 |
| Net Gain on Sale of Assets | $0 |
| Capital Gain Net Income | $0 |
| Net ST Capital Gain | $0 |
| Income Modifications | $0 |
| Profit on Inventory Sales | $0 |
| Other Income | $0 |
| Total Revenue | $31,474 |
| Statement of Expenses | |
|---|---|
| Compensation of officers, directors, trustees, etc | $0 |
| Other employee salaries and wages | $32,210 |
| Pension plans, employee benefits | $1,601 |
| Interest | $0 |
| Taxes | $5,917 |
| Depreciation | $0 |
| Occupancy | $0 |
| Travel, conferences, and meetings | $0 |
| Printing and publications | $0 |
| Other expenses | $615 |
| Total operating and administrative expenses | $57,333 |
| Contributions, gifts, grants paid | $0 |
| Total expenses and disbursements | $57,333 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $0 |
| Savings and temporary cash investments | $0 |
| Net Accounts receivable | $0 |
| Net Pledges Receivable | $0 |
| Grants receivable | $0 |
| Receivables from Officers, Directors, or Controlling Persons | $0 |
| Net other notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $0 |
| Net Investments - land, buildings, equipment | $0 |
| Investments—mortgage loans | $0 |
| Investments—other | $0 |
| Net Land, buildings, and equipment | $0 |
| Other assets | $0 |
| Total assets | $0 |
| Accounts payable and accrued expenses | $322,711 |
| Grants payable | $0 |
| Deferred revenue | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Mortgages and other notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $322,711 |
Peer Organizations
| Organization Name | Assets | Revenue |
|---|---|---|
Premier Community Health Dayton, OH | $3,886,537 | $6,142,148 |
Abraham J And Phyllis Katz Cord Blood Foundation Cleveland, OH | $4,596,233 | $6,882,274 |
Lung Cancer Research Foundation New York, NY | $5,738,095 | $6,154,252 |
Samuel Waxman Cancer Research Foundation New York, NY | $4,834,675 | $2,510,809 |
For Petes Sake Cancer Respite Foundation Plymouth Meeting, PA | $5,811,462 | $3,990,620 |
Laniado Development Fund Inc Monsey, NY | $541,683 | $1,706,128 |
American-Italian Cancer Foundation New York, NY | $5,209,552 | $1,660,961 |
Sbarro Health Research Organization Inc Philadelphia, PA | $1,818,007 | $1,444,668 |
Maple Tree Cancer Alliance Dayton, OH | $804,446 | $1,383,913 |
Stachestrong Inc Vestal, NY | $447,946 | $1,183,926 |
Arms Wide Open Childhood Cancer Foundation Marlboro, NJ | $332,441 | $1,049,867 |
Brem Foundation To Defeat Breast Cancer Inc Silver Spring, MD | $741,999 | $846,932 |